Levi & Korsinsky has opened a federal securities-law investigation into Procept Biorobotics Corp. over statements about revenue targets, pricing, and progress toward profitability. The probe follows a pricing change that reduced realized average selling prices, after which the company reported Q4 2025 revenue below prior guidance and issued 2026 revenue guidance that missed analyst expectations, contributing to a sharp one-day stock drop.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Procept Biorobotics Corporation published the original content used to generate this news brief via Newsfile (Ref. ID: 202603031544NEWSFILECNPR____20260303_286152_1) on March 03, 2026, and is solely responsible for the information contained therein.